Study #2017-0495
A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
MD Anderson Study Status
Not Accepting
Treatment Agent
Ruxolitinib, Navitoclax
Description
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis. Safety and efficacy data through 16 January 2023 are included in the interim analysis.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelofibrosis (MF)
Study phase:
Phase II
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-855-319-9556
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.